Advertisement

Topics

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

20:00 EDT 5 Jul 2019 | AAAS

(University of Texas M. D. Anderson Cancer Center) The 3-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Original Article: Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

NEXT ARTICLE

More From BioPortfolio on "Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...